SKYRIZI SY

SKYRIZI SY

SKYRIZI SY (Risankizumab-rzaa) is an FDA-approved subcutaneous injectable biologic therapy indicated for the treatment of moderate to severe plaque psoriasis in adult patients. Each 1×1 mL prefilled syringe contains 150 mg/mL of Risankizumab, designed for convenient self-administration or healthcare provider administration.

Risankizumab works by selectively inhibiting interleukin-23 (IL-23), a key cytokine involved in the inflammatory pathway of psoriasis. By targeting IL-23, SKYRIZI helps reduce plaque formation, relieve skin inflammation, and improve overall skin clearance, offering patients a targeted and effective long-term treatment option.

InfusionMed USA, based in Carrollton, Texas, supplies SKYRIZI SY and other dermatology therapies to clinics, hospitals, and specialty infusion centers across Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas areas. We ensure proper cold-chain storage, secure handling, and timely delivery for healthcare providers.

For subcutaneous injection under medical supervision or per prescribing guidance.

Download Form